[go: up one dir, main page]

AR050208A1 - Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento - Google Patents

Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Info

Publication number
AR050208A1
AR050208A1 ARP050103307A ARP050103307A AR050208A1 AR 050208 A1 AR050208 A1 AR 050208A1 AR P050103307 A ARP050103307 A AR P050103307A AR P050103307 A ARP050103307 A AR P050103307A AR 050208 A1 AR050208 A1 AR 050208A1
Authority
AR
Argentina
Prior art keywords
monoalkylamino
dialkylamino
haloalkyl
amino
alkyl
Prior art date
Application number
ARP050103307A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0417708A external-priority patent/GB0417708D0/en
Priority claimed from GB0508473A external-priority patent/GB0508473D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR050208A1 publication Critical patent/AR050208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

Compuesto de heteroaril sulfonamida sustituida de formula (1), una de sus sales, solvatos o profármacos farmacéuticamente aceptables en la que: R1 es alquilo C1-6, haloalquilo C1-6, alquenilo C2-6, amino, monoalquilamino C1-4 o dialquilamino C1-4; R2 y R3, que pueden ser iguales o diferentes, son H, halogeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-4, haloalcoxi C1-4, ciano, amino, monoalquilamino C1-4 o dialquilamino C1-4; cada R4, que pueden ser igual o diferente, es alquilo C1-6, halogeno, haloalquilo C1-6, alcoxi C1-4, haloalcoxi C1-4, ciano, nitro, amino, monoalquilamino C1-4 o dialquilamino C1-4; p es 0, 1 o 2; R5 y R6, que pueden ser iguales o diferentes, son H, halogeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-4, haloalcoxi C1-4, ciano, amino, monoalquilamino C1-4 o dialquilamino C1-4; y Het es tienilo, piridilo, pirimidinilo, piridazinilo, pirimidinilo, pirazinilo, imidazolilo, pirazolilo, pirrolilo, quinolilo, tiazolilo o furilo, cada uno de los cuales puede estar sustituido por uno o más grupos independientemente seleccionados entre alquilo C1-6, alcoxi C1-6, acetilo, halogeno, haloalquilo C1-6, ciano, nitro, amino, monoalquilamino C1-4 y dialquilamino C1-4. Procedimiento para la preparacion de dicho compuesto y composicion farmacéutica que lo comprende. Uso del compuesto para preparar un medicamento util para el tratamiento o la prevencion de una enfermedad o afeccion producida por una reduccion o desequilibrio en la funcion receptora del glutamato, como ser la esquizofrenia.
ARP050103307A 2004-08-09 2005-08-08 Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento AR050208A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0417708A GB0417708D0 (en) 2004-08-09 2004-08-09 Compounds
GB0508473A GB0508473D0 (en) 2005-04-26 2005-04-26 Compounds

Publications (1)

Publication Number Publication Date
AR050208A1 true AR050208A1 (es) 2006-10-04

Family

ID=35045372

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103307A AR050208A1 (es) 2004-08-09 2005-08-08 Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento

Country Status (21)

Country Link
US (2) US7618969B2 (es)
EP (2) EP1781614B1 (es)
JP (1) JP4901735B2 (es)
KR (1) KR20070050070A (es)
CN (1) CN101035760B (es)
AR (1) AR050208A1 (es)
AT (2) ATE434608T1 (es)
AU (1) AU2005270377A1 (es)
BR (1) BRPI0514191A (es)
CA (1) CA2576254A1 (es)
DE (2) DE602005021407D1 (es)
ES (2) ES2329063T3 (es)
IL (1) IL181172A0 (es)
MA (1) MA28823B1 (es)
MX (1) MX2007001678A (es)
NO (1) NO20071234L (es)
NZ (1) NZ552979A (es)
PE (1) PE20060623A1 (es)
RU (1) RU2403242C2 (es)
TW (1) TW200619197A (es)
WO (1) WO2006015828A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2329063T3 (es) * 2004-08-09 2009-11-20 Glaxo Group Limited Compuestos que potencian el receptor de glutamato y sus usos en medicina.
KR100659088B1 (ko) * 2005-07-15 2006-12-21 삼성에스디아이 주식회사 디플루오로피리딘계 화합물 및 이를 이용한 유기 발광 소자
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
ATE502675T1 (de) 2006-11-03 2011-04-15 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0704939D0 (en) * 2007-03-14 2007-04-25 Glaxo Group Ltd Compounds
WO2008113795A1 (en) * 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711088D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
JP2011506551A (ja) 2007-12-19 2011-03-03 グラクソ グループ リミテッド Ａｍｐａ受容体増強化合物および医薬におけるその使用
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
GB0818071D0 (en) * 2008-10-02 2008-11-05 Glaxo Group Ltd Compounds
GB0821166D0 (en) * 2008-11-19 2008-12-24 Glaxo Group Ltd Compounds
GB0822425D0 (en) * 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
EP2417101B1 (en) * 2009-04-09 2013-10-23 Merck Sharp & Dohme B.V. Indane derivatives
JP5976011B2 (ja) 2011-04-05 2016-08-23 武田薬品工業株式会社 スルホンアミド誘導体およびその用途
US9242938B2 (en) 2011-11-22 2016-01-26 Beijing Medisan Technology Co., Ltd Glycine reuptake inhibitor and use thereof
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
CN114903134A (zh) * 2014-12-09 2022-08-16 以西结·戈兰 酒精饮料替代品
DK3230255T3 (da) 2014-12-09 2020-06-22 Ezekiel Golan Regulatorer af uhæmmet adfærd
GB201601301D0 (en) * 2016-01-25 2016-03-09 Takeda Pharmaceutical Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07233072A (ja) * 1993-12-28 1995-09-05 Tanabe Seiyaku Co Ltd 医薬組成物
PE20000944A1 (es) * 1998-07-31 2000-09-20 Lilly Co Eli Derivados de sulfonamida
AU5233699A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Sulfonamide derivatives
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
TR200103123T2 (tr) 1999-04-30 2002-04-22 Eli Lilly And Company Monofluoroalkil türevleri.
ES2225558T3 (es) 2000-06-13 2005-03-16 Eli Lilly And Company Derivados de sulfonamida.
DE60204882D1 (de) * 2001-05-30 2005-08-04 Lilly Co Eli Zykloalkenylsulfonamidderivate
ES2329063T3 (es) * 2004-08-09 2009-11-20 Glaxo Group Limited Compuestos que potencian el receptor de glutamato y sus usos en medicina.

Also Published As

Publication number Publication date
EP1944289B1 (en) 2010-05-19
EP1781614A1 (en) 2007-05-09
TW200619197A (en) 2006-06-16
US7572819B2 (en) 2009-08-11
KR20070050070A (ko) 2007-05-14
MA28823B1 (fr) 2007-08-01
CA2576254A1 (en) 2006-02-16
MX2007001678A (es) 2007-04-12
WO2006015828A1 (en) 2006-02-16
PE20060623A1 (es) 2006-07-01
EP1781614B1 (en) 2009-06-24
ATE468326T1 (de) 2010-06-15
AU2005270377A1 (en) 2006-02-16
NO20071234L (no) 2007-05-08
CN101035760A (zh) 2007-09-12
US20080194648A1 (en) 2008-08-14
JP4901735B2 (ja) 2012-03-21
US7618969B2 (en) 2009-11-17
ES2329063T3 (es) 2009-11-20
IL181172A0 (en) 2007-07-04
JP2008509180A (ja) 2008-03-27
ATE434608T1 (de) 2009-07-15
NZ552979A (en) 2010-02-26
DE602005015119D1 (de) 2009-08-06
EP1944289A1 (en) 2008-07-16
CN101035760B (zh) 2011-03-02
US20070161638A1 (en) 2007-07-12
ES2346017T3 (es) 2010-10-07
DE602005021407D1 (de) 2010-07-01
RU2403242C2 (ru) 2010-11-10
RU2007108536A (ru) 2008-09-20
BRPI0514191A (pt) 2008-06-03

Similar Documents

Publication Publication Date Title
AR050208A1 (es) Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
AR049126A1 (es) Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing.
UY28526A1 (es) Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP045483A (es) Derivados de heteroarilamida benzocondensada de tienopiridinas útiles como agentes terapéuticos, composiciones farmacéuticas que incluyen a los mismos, y métodos para su uso
BRPI0616574A2 (pt) derivado de sulfonamida tendo atividade antagonìstica de receptor de pgd2
AR066583A1 (es) Derivados de 3,3-espiroindolinona
UY28186A1 (es) N-arilheterociclos sustituidos, procedimientos para su preparación, y su empleo como medicamentos.
EA200802007A1 (ru) Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
UY29177A1 (es) Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
UY28946A1 (es) Compuestos de aril-y heteroaril-alquilanina que contienen pirazol, composiciones farmacéuticas que contienen los compuestos y nuevos productos químicos intermedios
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
AR066659A1 (es) Derivados de espiroindolinona
AR072791A1 (es) DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER.
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
GT200600164A (es) Derivados de dihidrobenzofuranos y usos de los mismos
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR049711A1 (es) Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ECSP056115A (es) ANTAGONISTAS DEL RECEPTOR A2a DE 2-ALQUINIL- Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA ADENOSINA
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal